Skip to main content
. 2020 Jun 8;2(2):otaa045. doi: 10.1093/crocol/otaa045

Figure 4.

Figure 4.

Respondent knowledge of MC and regulatory pathways in Australia. The majority of respondents were unaware of current regulatory approaches to MC and of product/formulations available. N = 90 responses (n = 89 for “formulation” and “knowledge of effects” items). Percentage of total responses shown. MC, medicinal cannabis; IBD, inflammatory bowel disease.